CAMELLIA-TIMI 61 : Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
CAMELLIA-TIMI 61 : Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
• Lorcaserin (Belviq™) had better long-term weight loss when compared with placebo, without an increased risk for CV-related events.
• Lorcaserin is FDA approved for chronic weight management (FDA, 2012).
• Most common side effects include headaches, nausea, and dizziness. No difference in the risk of FDA-defined valvulopathy when compared with placebo (The BLOSSOM trial)
Update from February 2020 – Lorcaserin was withdrawn from the US market by the FDA due to an increased risk for cancer among patients exposed to it in a clinical trial.
Infographic
Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM; CAMELLIA–TIMI 61 Steering Committee and Investigators. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med. 2018 Sep 20;379(12):1107-1117.
